NM32-2668

N/A

Report date: 2026/03/19 17:18:38

Base Information

Drug NameNM32-2668
Drug Alias NameNM-32-2668
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-Inactive tyrosine-protein kinase transmembrane receptor ROR1Anti-CD3Anti-Serum albumin +[4] 
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1T cell surface glycoprotein CD3Serum albumin
Therapy Area/IndicationsEndometrial NeoplasmsFallopian Tube NeoplasmsEsophageal Neoplasms +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNumab Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesNumab Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsEndometrial NeoplasmsFallopian Tube NeoplasmsEsophageal Neoplasms +[13] 

Other Information

ATC CodeN/A
Related LinksN/A